Literature DB >> 16779504

Successful treatment of refractory rash in paraneoplastic amyopathic dermatomyositis.

Spyros Aslanidis1, Athina Pyrpasopoulou, Nikoleta Kartali, Chryssanthos Zamboulis.   

Abstract

Skin involvement in dermatomyositis does not always parallel muscle disease and can be the most active or severe component of the disease, failing to respond to therapeutic interventions that are adequate for myositis and other systemic involvement. This case refers to a resistant paraneoplastic amyopathic dermatomyositis rash which readily resolved with intravenous immunoglobulin (IVIG), practically in the form of monotherapy. This observation gains particular significance considering that IVIG is still regarded as a second-line therapeutic regimen in the treatment of dermatomyositis despite its prevalence in matters of safety.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16779504     DOI: 10.1007/s10067-006-0337-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  11 in total

1.  Skin metastasis of breast cancer clinically undistinguished from amyopathic dermatomyositis.

Authors:  M Seishima; H Shimizu; Z Oyama
Journal:  Eur J Dermatol       Date:  2001 Mar-Apr       Impact factor: 3.328

Review 2.  Dermatomyositis and drugs.

Authors:  A L Dourmishev; L A Dourmishev
Journal:  Adv Exp Med Biol       Date:  1999       Impact factor: 2.622

3.  A case of refractory adult dermatomyositis.

Authors:  A J Whallett; T J Gillott; R Klocke; J S Coppock
Journal:  Br J Rheumatol       Date:  1998-05

4.  High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels.

Authors:  I Göttfried; A Seeber; B Anegg; A Rieger; G Stingl; B Volc-Platzer
Journal:  Eur J Dermatol       Date:  2000 Jan-Feb       Impact factor: 3.328

Review 5.  The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile.

Authors:  Marinos C Dalakas
Journal:  Pharmacol Ther       Date:  2004-06       Impact factor: 12.310

6.  Paraneoplastic syndromes: detection of malignant tumors using [(18)F]FDG-PET.

Authors:  U Berner; C Menzel; D Rinne; S Kriener; N Hamscho; N Döbert; M Diehl; R Kaufmann; F Grünwald
Journal:  Q J Nucl Med       Date:  2003-06

Review 7.  Skin involvement in dermatomyositis.

Authors:  Beth Santmyire-Rosenberger; Elizabeth M Dugan
Journal:  Curr Opin Rheumatol       Date:  2003-11       Impact factor: 5.006

8.  Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy.

Authors:  M M Joffe; L A Love; R L Leff; D D Fraser; I N Targoff; J E Hicks; P H Plotz; F W Miller
Journal:  Am J Med       Date:  1993-04       Impact factor: 4.965

Review 9.  Skin manifestations of systemic autoimmune connective tissue disease: diagnostics and therapeutics.

Authors:  Richard D Sontheimer
Journal:  Best Pract Res Clin Rheumatol       Date:  2004-06       Impact factor: 4.098

Review 10.  Adult inflammatory myopathies.

Authors:  Lisa Christopher-Stine; Paul H Plotz
Journal:  Best Pract Res Clin Rheumatol       Date:  2004-06       Impact factor: 4.098

View more
  2 in total

Review 1.  Pneumomediastinum and subcutaneous emphysema secondary to amyopathic dermatomyositis with cryptogenic organizing pneumonia in invasive breast cancer: a case report and review of literature.

Authors:  Sung Hwan Park; Yoon-Seup Kum; Kyung-Chan Kim; Jung-Yoon Choe; Sung-Hoon Park; Seong-Kyu Kim
Journal:  Rheumatol Int       Date:  2008-12-18       Impact factor: 2.631

2.  Dermatomyositis Associated with Myelofibrosis following Polycythemia Vera.

Authors:  Naomi Fei; Sarah Sofka
Journal:  Case Rep Hematol       Date:  2017-06-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.